Q32 Bio Inc. 35H.F Stock
Q32 Bio Inc. Price Chart
Q32 Bio Inc. 35H.F Financial and Trading Overview
| Q32 Bio Inc. stock price | 0.83 EUR |
| Previous Close | 0.93 EUR |
| Open | 0.9 EUR |
| Bid | 0.9 EUR x 0 |
| Ask | 0.93 EUR x 0 |
| Day's Range | 0.9 - 0.9 EUR |
| 52 Week Range | 0.79 - 2.97 EUR |
| Volume | 8K EUR |
| Avg. Volume | 57 EUR |
| Market Cap | 52.27M EUR |
| Beta (5Y Monthly) | -0.072535 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.2 EUR |
35H.F Valuation Measures
| Enterprise Value | -67463840 EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.37499997 |
| PEG Ratio (5 yr expected) | 0.46 |
| Price/Sales (ttm) | 16.294403 |
| Price/Book (mrq) | 0.34246573 |
| Enterprise Value/Revenue | -21.03 |
| Enterprise Value/EBITDA | 0.553 |
Trading Information
Q32 Bio Inc. Stock Price History
| Beta (5Y Monthly) | -0.072535 |
| 52-Week Change | -42.89% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.97 EUR |
| 52 Week Low | 0.79 EUR |
| 50-Day Moving Average | 0.91 EUR |
| 200-Day Moving Average | 1.34 EUR |
35H.F Share Statistics
| Avg. Volume (3 month) | 57 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 57.79M |
| Float | 30.78M |
| Short Ratio | N/A |
| % Held by Insiders | 9.18% |
| % Held by Institutions | 47.46% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3839.58% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.25% |
| Return on Equity (ttm) | -60.24% |
Income Statement
| Revenue (ttm) | 3.21M EUR |
| Revenue Per Share (ttm) | 0.06 EUR |
| Quarterly Revenue Growth (yoy) | 0% |
| Gross Profit (ttm) | -95143000 EUR |
| EBITDA | -122004000 EUR |
| Net Income Avi to Common (ttm) | -125954000 EUR |
| Diluted EPS (ttm) | -1.89 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 150.02M EUR |
| Total Cash Per Share (mrq) | 2.6 EUR |
| Total Debt (mrq) | 29.1M EUR |
| Total Debt/Equity (mrq) | 19.16 EUR |
| Current Ratio (mrq) | 8.299 |
| Book Value Per Share (mrq) | 2.628 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -109031000 EUR |
| Levered Free Cash Flow (ttm) | -65527752 EUR |
Profile of Q32 Bio Inc.
| Country | Germany |
| State | MA |
| City | Bedford |
| Address | One Patriots Park |
| ZIP | 01730 |
| Phone | 781 301 7277 |
| Website | https://www.homologymedicines.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 92 |
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Q&A For Q32 Bio Inc. Stock
What is a current 35H.F stock price?
Q32 Bio Inc. 35H.F stock price today per share is 0.83 EUR.
How to purchase Q32 Bio Inc. stock?
You can buy 35H.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Q32 Bio Inc.?
The stock symbol or ticker of Q32 Bio Inc. is 35H.F.
Which industry does the Q32 Bio Inc. company belong to?
The Q32 Bio Inc. industry is Biotechnology.
How many shares does Q32 Bio Inc. have in circulation?
The max supply of Q32 Bio Inc. shares is 3.23M.
What is Q32 Bio Inc. Price to Earnings Ratio (PE Ratio)?
Q32 Bio Inc. PE Ratio is 0.00000000 now.
What was Q32 Bio Inc. earnings per share over the trailing 12 months (TTM)?
Q32 Bio Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Q32 Bio Inc. company belong to?
The Q32 Bio Inc. sector is Healthcare.